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Role of protein kinase C on the acute desensitization of renal cortical
adenylate cyclase to parathyroid hormone. The mechanisms of adenylate
cyclase desensitization to parathyroid hormone are still unclear. Current
evidence suggest that the signal generated after PTH binding to receptors
results in activation of adenylate cyclase and stimulation of phospholipase
C with subsequent activation of protein kinase C. Recent studies have
suggested a role of protein kinase C on the regulation of the PTH-depen-
dent receptor-adenylate cyclase system in cultured cells. Therefore, the
present studies were conducted to examine the role of protein kinase C on
the desensitization of canine renal cortical adenylate cyclase after an acute
exposure in vivo to PTH. A group of normal dogs were treated with a
single intravenous injection of 1 ig/k of syn bPTH (1-34) or Nle bPTH
(3-34). Ten minutes later, animals were subjected to bilateral nephrectomy
and the kidney cortex processed for preparations of basolateral mem-
branes for determinations of adenylate cyclase activity, as well as mem-
brane and cytosolic fractions for analysis of protein kinase C activity.
Animals not treated with PTH were used as controls. PTH administration
in vivo resulted in a 46.9 9.3% decrease in maximal adenylate cyclase
activity in vitro in response to syn bPTH (1-34) (P < 0.001). Likewise, PTH
binding as measured with '251-N1e8'18,Tyr34-bPTH (1-34)NH2 showed a 40
3% decrease. This alterations were associated with a marked translo-
cation of protein kinase C from the cytosol to the membrane. Thus,
protein kinase C activity in membrane fractions increased from 160.6
44.8 pmol Pi/min in controls to 500.4 123 in PTH treated dogs (P <
0.03). Conversely, cytosolic activity decreased from 492.3 100 pmol
Pi/min in controls to 260 127 in PTH treated animals. Treatment of the
animals with Nie bPTH (3-34) also resulted in translocation of protein
kinase activity of similar magnitude. These data indicate that acute
homologous desensitization of the receptor-adenylate system after PTH
administration in vivo occurs in association with translocation of protein
kinase C activity, suggesting a role of this system in the mechanism of
desensitization of adenylate cyclase to the hormone.
Current evidence indicate that the action of PTH is initiated
with the binding of the hormone to specific receptors in target
cells. The signal generated from this interaction is transduced by
G proteins that lead not only to activation of adenylate cyclase
[1—5], but also to stimulation of phospholipase C, leading to an
increase in intracellular calcium concentration and activation of
protein kinase C [6—10]. The precise roles of each of these
pathways on the final biological actions of the hormone are still
under investigation. In addition to date it is not clear whether
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these two pathways are integrated in the mechanisms of regula-
tion of PTH action.
The response of adenylate cyclase to hormones and neurotrans-
mitters attenuates rapidly despite continuous exposure of the cell
to the agonist. This phenomenon known as desensitization has
been demonstrated in a variety of hormone receptor systems,
including the PTH-receptor-cyclase complex [11—16]. Previous
studies in isolated perfused kidneys have advanced evidence
supporting receptor occupancy as a mechanism for short-term
desensitization to PTH [14]. In nutritionally induced hyperpara-
thyroidism the evidence suggests that desensitization occurs as a
consequence of uncoupling of the receptor-adenylate cyclase
system, probably as a result of alterations in signal transduction by
G proteins [15]. More recently, it has been shown that phorbol
esters inhibit PTH-stimulated cyclic AMP accumulation in opos-
sum kidney cells and that inhibition of protein kinase C blocks the
desensitization to PTH, suggesting a role of protein kinase C in
the regulation of the PTH receptor adenylate cyclase system in
that cell line [17, 18]. Therefore, the present studies were designed
to examine a possible role of protein kinase C on the mechanism
of desensitization of canine renal cortical adenylate cyclase after a
rapid exposure to PTH in vivo.
Methods
Materials
Synthetic bovine PTH (1-34) [syn bPTH (1-34)], Nle8'18,Tyr34-
bPTH (3-34) [NIe bPTH (3-34)], N1e8"8,Tyr34-bPTH (1-34)NH2,
ATP, 5 'guanylylimidodiphosphate [Gpp(NH)p], H-7, diolein,
Histone IIIC, phosphatidylserine, and other reagents were pur-
chased from Sigma Chemical (St. Louis, MO, USA). 125j and
132P-ATP were obtained from New England Nuclear (Boston,
MA, USA). '251-Adenosine 3'S'-cyclic monophosphate, and 125I
Nle8"8,Tyr34-bPTH (1-34)NH2 were prepared in our laboratory as
previously described [4, 5].
Methods
Studies were performed in 13 adult mongrel dogs maintained
on a standard dog chow. The animals were anesthetized with
pentobarbital sodium (30 mg/kg i.v.). Ten minutes prior to
removal of kidneys, five dogs from the experimental group
received 1 xg per kilo of body weight of syn bPTH (1-34) in a
single i.v. injection. Five dogs in the control group received no
PTH. A third group of three animals received a single i.v. injection
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(1 g/k) of Nle bPTH (3-34). The kidneys were then removed and
perfused with ice-cold normal saline to remove residual blood.
Basolateral membranes for determination of adenylate cyclase
activity and PTH-receptor binding were prepared from the cortex
by differential centrifugation and discontinuous sucrose density
gradient ultracentrifugation as previously described [4, 5]. Protein
concentration in membrane preparations was determined by the
method of Lowry et a! [19].
Purification of protein kinase C
A portion of renal cortex was processed for purification of
protein kinase C in membrane and cytosolic fractions according to
the methods of Abou-Samra et al [10] with some modifications.
Cortex was minced with a fine blade and homogenized in a buffer
consisting of 50 mivi Tris-HC1 pH 7.5, 250 m sucrose, 0.2 mM
EDTA, 0.2 mrvi EGTA, 0.5 mrvi phenylmethylsulfonylfluoride
(PMSF), 2 mi dithiothreitol, 10 g/ml aprotinin, 10 g/ml
leupeptin, in a ratio of 1 g tissue per 5 ml buffer. The mixture was
then homogenized with 22 strokes in a teflon-glass homogenizer.
The volume of homogenate was completed to 12.5 ml with the
homogenization buffer and centrifuged at 700 X g for 10 minutes
at 4°C. The supernatant was centrifuged at the same speed for 20
minutes. The volume of supernatant was reconstituted to 12.5 ml
and centrifuged at 100,000 x g, using a swinging bucket rotor
SW4O-Ti for 60 minutes at 4°C. The supernatant was separated
and stored as the cytosolic fraction. The pellet was resuspended to
12.5 ml of solubilization buffer consisting of 20 mivi Tris-HC1 pH
7.5, 0.05 mM EDTA. 0.05 mis EGTA 0.5 m'vi PMSF, 2 m
dithiotrietol, 10 g/ml aprotinin, 10 tg leupeptin, 1% Nonidet
P-40. The mixture was stirred at 4°C for one hour. The suspension
was centrifuged at 500 x g per five minutes at 4°C to obtain the
membrane fraction in the supernatant. Both cytosolic and mem-
brane fractions were subjected to ion exchange chromatography
on DEAE-cellulose (DE52, Whatman). The columns were equil-
ibrated with 20 m Tris-HC1 pH 7.5, 0.05 mM EDTA, 0.05 mM
EGTA, 0.5 mi PMSF, 2 mi dithiotrietol and 1% Nonidet P-40.
Protein kinase C was eluted in fractions of 1 ml, using 20 mM
Tris-HC1 pH 7.5, 0.05 mrvt EDTA, 0.05 mM EGTA, 0.5 mM PMSF,
2 mrvi dithiotrietol, 10 tg/ml aprotinin, 10 jg leupeptin, 0.05%
Nonidet P-40 and 150 mrvi NaC1. Protein was measured by the
method of Lowry et al [19]. Fractions with the highest protein
concentration were aliquoted in 30% glycerol and stored at
—80°C for determination of protein kinase C activity.
Adenylate cyclase assay
Adenylate cyclase activity in membrane preparations was de-
termined by quantitation of cyclic AMP generation from ATP as
previously described [4, 5]. Incubations were performed at 25°C
for 30 minutes in a final volume of 100 tl. The incubation mixture
consisted of 50 mivi Tris-HC1 pH 7.5, 10 mivi MgCl2, 25 mtvi KCI,
0.2 mrvi EDTA, 1 mi IBMX, 0.2 mivi ATP, 25 mii phosphocre-
atine, 5% hypoparathyroid serum and 1 mg/mi creatine phos-
phokinase. PTH, Gpp(NH)p, NaF or MnC12 were added at the
indicated concentrations when required. The reaction was fin-
ished by boiling the samples for three minutes. Cyclic AMP was
determined by radioimmunoassay as previously described [14].
Protein kinase C assay
These experiments were carried out using the method of
Abou-Samra et al [10] with some modifications. Cytoslic or
Fig. 1. Dose-response of adenylate cyclase activity to syn bPTH (1-34) in
basolateral renal cortical membranes from controls (•) and syn bPTH (1-34)
(A) treated animals. Experiments were performed as described in Meth-
ods. Points are mean SEM of five experiments in each group performed
in duplicate. Basal adenylate cyclase activity (351 30.1 in controls and
327 33.2 pmol cAMP/mg protein/30 mm in PTH-treated dogs, respec-
tively) was subtracted from all points.
membrane fractions (3 to 5 j.g protein of the DEAE-cellulose
fraction) were incubated for four minutes at 30°C in an assay
mixture containing 25 mM Tris-HC1, pH 7.5, 10 mi MgC12, 0.1 mM
CaCl2, 1 mM f3-mercaptoethanol, 20 g of histone-IIIS, 10 ,LM
32PATP (0.4 j.Ci/tube; 600 to 800 cpm/pmol), in the presence or
absence of 2 tg phosphatidylserine and 1.242 g diolein in a final
volume of 100 M1 The incubation was terminated by transferring
25 ai of the assay mixture onto 1 X 1.5 cm Whatman 3M filter
paper, which was immediately immersed in 10% TCA, 20 mM
pirophosphate. The TCA-pirophosphate was discarded and the
filter paper was washed with 2.5 ml of the same solution overnight.
The following day the paper was washed with the same solution,
and then with acetone. The filter paper was allowed to dry,
transferred to a scintillation vial and counted using scintillation
fluid in a j3 counter (LKB Wallack Redirack).
Receptor binding assay
PTH receptor binding was assessed using '251-N1e8"8,Tyr34-
bPTH (1-34)NH2 as radioligand as previously described [3—5].
Basolateral membranes (20 to 40 jg protein) were incubated in
duplicate with 30,000 to 50,000 counts/minute of radioligand (sp.
act. 290 jCi/g) in 50 mrt Tris-HCI, pH 7.5, 25 mM KC1, and 5%
hypoparathyroid canine serum. Syn bPTH (1-34) was added at
various doses as indicated. Incubations were performed at 16°C
for 60 minutes. Free radioligand was separated by microcentrifu-
gation. Nonspecific binding measured in the presence of io M
syn bPTH (1-34) was 5%.
Statistical analysis
Results are expressed as mean SEM. Student's t-test was used
to determine the significance of differences between groups.
Results
Desensitization of adenylate cyclase to PTH
Figure 1 illustrates the effect of pretreating the animals for 10
minutes with 1 tg/k of syn bPTH (1-34) on the subsequent
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Fig. 2. Dose-response of adenylate cyclase activity to synthetic bPTH (1-34)
in basolateral renal cortical membranes from controls (S) and animals
treated with syn bPTH (3-34) (A) in vivo. Experiments were performed as
described in Methods. Points are mean SaM of five experiments in each
group performed in duplicate. Basal adenylate cyclase activity was sub-
tracted from all points.
response of adenylate cyclase in basolateral renal cortical mem-
branes to a further challenge with the hormone. The dose-
response curve of adenylate cyclase to syn bPTH (1-34) was
markedly decreased compared to membranes from control dogs
not pretreated with PTH. Adenylate cyclase activity at the maxi-
mal stimulating concentration (10 M) of syn bPTH (1-34) was
reduced from 1932 149 to 1131 73 pmol cyclic AMP/mg
protein/30 mm (P < 0.001). Desensitization was also evident at
lower PTH concentrations. The hormone concentration required
for half-maximal stimulation of adenylate cyclase (Kact) was
unchanged by desensitization.
As shown in Figure 2, the treatment of an additional group
of animals with equimolar dose of Nle bPTH (3-34) in substi-
tution for synthetic bPTH (1-34) resulted in a similar degree of
desensitization of adenylate cyclase to a new challenge with syn
bPTH (1-34). However, incubation of membranes from control
and PTH treated animals with increasing concentrations of Nle
bPTH (3-34) in the range of 10b0 to iO M did not stimulate
adenylate cyclase.
Basal enzyme activity was not statistically different in mem-
branes from both PTH-treated groups and controls. Also, basal
activity in the presence of MnCl2 in substitution for MgCl2 was
unchanged by previous exposure to PTH (Fig. 3).
Effect of sodium fluoride and guanylylimidodiphosphate
To examine whether exposure to PTH may affect nonhormonal
stimulation of adenylate cyclase, membranes were incubated in
the presence of 10 mrvi NaF or 0.1 mrvi Gpp(NH)p. As shown in
Figure 3, response to NaF and Gpp(NH)p was unaffected by
previous exposure to either species of PTH, indicating that
desensitization is not heterologous.
Effect on PTH receptor binding
Figure 4 shows the displacement of the radioligand 125J
Nle8'18,Tyr34-bPTH (1-34)NH2 binding to basolateral renal corti-
cal membranes by increasing concentrations of syn bPTH (1-34).
Pretreatment of the animals with syn bPTH (1-34) inhibited
specific binding from 30% 4 to 12% 2 compared to controls
(P < 0.01). This reduction in hormone binding was a consequence
of a decrease in the maximal number of binding sites without
alterations in binding affinity.
Effect on protein kinase C activity
To determine whether alteration of protein kinase C activity
may relate with the desensitization to PTH, the enzyme activity
was determined in preparations of cytosol and membrane frac-
tions from controls and PTH-treated animals. As illustrated in
Figure 5A, under basal conditions (controls) protein kinase C
activity was high in cytosol (492 100 pmol Pi/mg prot/min) and
low in the membrane fractions (160 44.8 pmol Pi/mg prot/min).
Exposure to syn bPTH (1-34) for 10 minutes in vivo (Fig. 5B)
resulted in a marked increase in membrane-associated protein
kinase C activity to 500.4 123 pmol Pi/mg prot/min (P < 0.03),
with a concomitant decrease in cytosolic activity to 260 127
pmol Pi/mg prot/min (P < 0.03). Therefore, as shown in Figure 6,
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Fig. 3. Effect of NaF (, 10mM), Gpp(NH)p ( i0M) and MnCl2(LI], 20 mM) on adenylate cyclase activity in basolateral renal cortical
membranes from control and PTH-treated dogs. In the experiments with
MnC12, MgCI2 was omitted from the incubation medium.
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Fig. 4. Displacement of 1251-Nle8, Nle18, Tyr34 bPTH (1-34) NH2 binding
by synthetic bPTH (1-34) in basolateral membranes from control (I) and syn
bPTH (1-34)-treated (A) dogs.
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protein kinase C translocation ratio (membrane activity/cytosol
activity) increased from 0.34 0.06 to 2.39 0.51 (P < 0.007).
Pretreatment of the animals with Nle bPTH (3-34) also resulted
in an increase in protein kinase C activity in the membrane (475
186 pmol Pilmg prot/min) and a concomitant decrease in the
activity in the cytosolic fraction (31 7 pmol Pilmg prot/min, P <
0.006).
Discussion
The signal originated after the interaction of PTH with specific
receptors in the kidney is transduced by U proteins that lead to
activation of at least two different metabolic pathways: signal
transduction by Us results in adenylate cyclase activation with
generation of cyclic AMP and activation of cyclic AMP-dependent
protein kinase [7, 9, 20—22], whereas transduction by other G
proteins results in activation of phospholipase C, leading to an
increase in the production of 1P3 and diacyiglycerol with subse-
quent rise in cytosolic calcium and activation of protein kinase C
[5, 6, 8—10]. The precise role of each of these pathways in the final
action of the hormone is not clear at the present time, but recent
evidence suggests that both mechanisms may modulate the hor-
Fig. 5. A. Protein kinase C activity in membrane
(D) and cytosolic () fractions of renal cortex
from control animals. B. Protein kinase C
activity in membrane fractions of renal cortex
from dogs treated with syn bPTH (1-34).
Experiments were performed in five
preparations of membrane or cytosolic
fractions, respectively. Values are mean SCM.
mone action in a complementary or counter-regulatory fashion [8,
20]. Particularly, protein kinase C has been shown to play an
important role in the desensitization of adenylate cyclase to PTH
and other hormones in cultured cell lines [17, 18]. However, it is
not clear whether interactions between these two pathways may
be involved in the mechanisms of acute desensitization in vivo.
In the present studies we demonstrate that the acute adminis-
tration of a single intravenous dose (1 pg/k) of syn bPTH (1-34)
or Nle bPTH (3-34) to normal dogs results in rapid desensitization
of renal cortical adenylate cyclase to further challenge in vitro with
PTH. This state was accompanied by an equivalent reduction in
PTH receptor binding. The desensitization was homologous, since
nonhormonal activation of adenylate cyclase was normal, as
demonstrated by normal response to NaF and Gpp(NH)p.
Several mechanisms operating at the receptor level or at other
components of the receptor-adenylate cyclase system have been
implicated in the desensitization to different hormones. Studies in
other hormone-dependent adenylate cyclase systems suggest that
the desensitization phenomenon may be biphasic. Rapid desensi-
tization may be essentially complete within 30 minutes of expo-
sure of cells to micromolar concentrations of the hormone
[23—25]. Further desensitization requires a more prolonged expo-
sure to the hormone [26].
In the case of PTH-dependent adenylate cyclase, the evidence
today indicates that the mechanisms underlying rapid desensiti-
zation are different from those operating when exposure to the
hormone have been chronic or prolonged. Thus, the attenuation
of the adenylate cyclase response after exposure of isolated
perfused kidneys to PTH for 20 hours was associated with
occupation of receptors, which could be reversed after dissocia-
tion of bound PTH when membranes were preincubated with
GTP [14]. Desensitization under these conditions was homolo-
gous. Whereas, in chronic hyperparathyroidism induced by cal-
cium deficient diet [15], in vitamin D deficient rats [26] and in
senescent rats [27] desensitization was heterologous, and the
evidence strongly suggests that the mechanisms involve alterations
in G proteins. Our results may suggest rapid desensitization
involving occupation of receptors. However, it is possible that
other mechanisms acting concurrently may play important roles at
different levels of the desensitization process, as has been shown
for protein kinase C and other kinase systems [26].
To examine whether protein kinase C may be involved in the
desensitization after a brief exposure to PTH in vivo, we deter-
mined the effect of the hormone on the activity of protein kinase
C in cytosol and membrane fractions. Our studies demonstrate
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Fig. 6. Effect of an intravenous injection of syn bPTH (1-34) on the
translocation ratio of protein kinase C (membrane activily/cytosolic activity),
P < 0.001. Data are presented in Figure 5.
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that under basal conditions the dog kidney cortex contains a high
activity of cytosolic protein kinase C. After an acute exposure to
syn bPTH (1-34) there was a rapid increase in protein kinase C
activity in the membrane with concomitant reduction in cytosolic
activity. Thus, the protein kinase C translocation ratio increased
sevenfold in animals that received PTH in comparison with
animals not treated with the hormone.
Although the demonstration of simultaneous induction of
translocation of protein kinase C and adenylate cyclase desensi-
tization after a short exposure to PTH may only reflect the action
of the hormone through two different pathways, it seems possible
a cause-effect relationship between the two hormone-dependent
effects. Indeed, as shown by Pernalete et al [18] in cultured
opossum kidney cells, the acute exposure to PTH resulted in
decreased stimulation of cyclic AMP response to further chal-
lenge with the hormone. Similar loss of cyclic AMP response to
PTH was induced by treatment of the cells with phorbol ester, a
known activator of protein kinase C. In addition, inhibitors of
protein kinase C completely prevented desensitization to PTH.
Other studies have recently provided additional evidence in
support of a role of protein kinase C in the desensitization of the
rat osteosarcoma cell line, UMR-106 [17] and human osteoblast-
like SaOs-2 [28] to PTH. In these studies they demonstrated that
in both, PTH and phorbol ester treated cells, desensitization to
the hormone occurred concomitantly with a decrease in PTH
receptor number, suggesting that the mechanism involves, at least
in part, a direct effect of protein kinase C on the PTH receptor
[28].
It seems unlikely that the desensitization to PTH observed in
the present studies may be a consequence of an effect of cyclic
AMP or protein kinase A on the PTH receptor as has been shown
for PTH and other hormones in other systems [26]. Pretreatment
of the animals with Nle bPTH (3-34), a fragment that has been
shown to be a competitive antagonist of PTH-dependent adenyl-
ate cyclase in many systems in vitro [29—31], also induced desen-
sitization of adenylate cyclase to PTH and translocation of protein
kinase C activity in the present studies. These effects are consis-
tent with previous observations indicating that Nle bPTH (3-34)
has differential activity on cyclic AMP, inositol trisphosphate,
mobilization of intracellular calcium and activation of protein
kinase C [31, 32]. Indeed, it has been shown that removing the first
two N-terminal amino acids to produce the PTH (3-34) fragment
eliminates its ability to stimulate adenylate cyclase while retaining
its property to activate protein kinase C in ROS 17/2 cells and S49
cyc T-lymphoma cells [34], indicating that the structure-function
requirements for activation of protein kinase C lies beyond the
first two amino acid residues of the hormone. More recent studies
have located the protein kinase C activation domain of PTH to
the 28-34 region [35].
Although some studies in vivo have shown that Nie bPTH
(3-34) may have some agonistic activity on the adenylate cyclase
system [36, 37], studies in vitro using cell lines in culture have been
contradictory. Thus, while recent studies in the rat osteosarcoma
cell line UMR-106 have failed to demonstrate agonistic activity of
this hormone fragment in the cyclic AMP/protein kinase A
systems [33], Abou-Samra et al [38] have shown a weak agonistic
activity of Nle bPTH (3-34) at high doses (1 M) in UMR-106-01
cells without any detectable activation of protein kinase A.
Interestingly, at that dose the fragment produced down-regulation
of the PTH receptor in a magnitude greater than would be
predicted on the basis of the weak stimulation of cyclic AMP. The
mechanism of receptor down-regulation induced by Nle bPTH
(3-34) is presumably mediated by non-cyclic AMP-dependent
mechanisms, since it was not blocked in the cyclic AMP-resistant
phenotype UMR 4-7 cells derived from UMR 106-01 cells,
whereas receptor regulation induced by syn bPTH (1-34) involved
cyclic AMP-dependent and non-cyclic AMP-dependent mecha-
nisms [38].
Other lines of evidence point to a role of protein kinase C and
other kinases in the mechanisms of desensitization to hormones,
particularly through phosphorylation of the -adrenergic receptor
[24—26, 39, 40]. However, interaction of protein kinase C with the
adenylate cyclase system may also occur at other levels, such as
other components of the system, including G proteins [41, 42] and
the catalytic unit [43].
Previous studies have shown that blood pressure may decrease
following a PTH injection [44, 45]. Therefore, and additional
aspect to be considered in the interpretation of the present results
is that protein kinase C activation may result from a secondary
increase in angiotensin II. Although the present studies do not
address this point directly, previous studies have shown that the
hypotensive effect of PTH is dose-dependent [45, 46]. Thus, in the
studies of Ellison and McCarron [45], the injection of 1 pg/k of
bPTH (1-34), a dose similar to that used in the present studies,
produced less than 10% fall in blood pressure. Interestingly, the
PTH analog Nie bPTH (3-34) did not produce hypotension even
at doses as high as 500 j.tg/k, indicating that the vasodilatory effect
of PTH resides in the first two amino acids. Thus, it seems unlikely
that the translocation of protein kinase C activity seen in the
present studies after the administration of bPTH (1-34) or Nle
bPTH (3-34) may be attributed to the known vascular effects of
bPTH (1-34).
In conclusion, the present studies demonstrate that acute
desensitization of the renal cortical adenylate cyclase system
occurs after rapid exposure to PTH in vivo. This phenomenon is
associated with rapid translocation of protein kinase C from the
cytosol to the membrane, suggesting an important role of protein
kinase C in the acute desensitization of adenylate cyclase to PTH,
probably by a direct effect on PTH receptors.
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